Effects of ramipril and enalapril on cerebral blood flow in elderly patients with asymptomatic carotid artery occlusive disease

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 1, 1996, Pages 48-52

  Patel, Rakesh V ^a   Ramadan, Nabih M ^a   Levine, Steven R ^a   Welch, K M A ^a   Fagan, Susan C ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Aging; Cerebral blood flow; Enalapril; Hypertension; Ramipril

Indexed keywords

AMILORIDE; ATENOLOL; CAPTOPRIL; DILTIAZEM; ENALAPRIL; FUROSEMIDE; LISINOPRIL; NIFEDIPINE; PLACEBO; RAMIPRIL; TRIAMTERENE;

ADULT; AGED; AGING; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BRAIN BLOOD FLOW; CAROTID ARTERY OBSTRUCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HUMAN; HYPERTENSION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VASCULAR RESISTANCE;

AGE FACTORS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAROTID ARTERY, INTERNAL; CAROTID STENOSIS; CEREBROVASCULAR CIRCULATION; ENALAPRIL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RAMIPRIL;

EID: 0030014764     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199607000-00008     Document Type: Article

References (24)

1. Baumbach GL, Heistad DD. Cerebral circulation in chronic arterial hypertension. Hypertension 1988;12:89-95.
2. Strangaard S. Cerebral ischemia caused by overzealous blood pressure lowering. Dan Med Bull 1987;34(suppl 1): 5-7.
3. Fagan SC, McCormick PW, Diaz FG. Hemodynamic vertebrobasilar insufficiency as an adverse effect of antihypertensive therapy. Drug Intell Clin Pharm 1989;23:238-9.
4. Strandgaard S, Haunso S. Why does antihypertensive treatment prevent stroke but not myocardial infarction? Lancet 1987;2:658-61.
5. Ruff RL, Talman WT, Petito F. Transient ischemic attacks associated with hypotension in hypertension associated with carotid stenosis. Stroke 1981;12:353-5.
6. Fagan SC, Robert S, Ewing JR, Levine RS, Ramadan N, Welch KMA. Cerebral blood flow changes with enalapril, Pharmacotherapy 1992;12:319-23.
7. Cohn JN, Johnson G, Ziensche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic heart failure. N Engl J Med 1991;325:303-10.
8. Pfeffer MA, Braunwald E, Moye LA. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
9. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
10. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Eng J Med 1987;316:1429-35.
11. Joint National Committee on detection, evaluation and treatment of high blood pressure. The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC-V). Arch Intern Med 1993;153: 154-83.
12. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
13. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
14. Dzau VJ. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol 1987;59:59A-65A.
15. Vasmant D, Bender N. The renin-angiotensin system and ramipril, a new converting enzyme inhibitor. J Cardiovasc Pharmacol 1989;14(suppl 4):S46-52.
16. Gohlke P, Scholkens B, Henning R, et al. Inhibition of converting enzyme in brain tissue and cerebrospinal fluid of rats following chronic oral treatment with the converting enzyme inhibitors ramipril and Hoe 288. J Cardiovasc Pharmacol 1989;14(suppl 4):S32-6.
17. Wei JY. Age and the cardiovascular system. N Engl J Med 1992;327:1735-9.
18. Robertson WM, Welch KMA, Tilley BC, Ewing JR. Cerebral blood flow asymmetry in the detection of extracranial cerebrovascular disease. Stroke 1988;19:813-9.
19. Meyer BH, Muller FO, Badian M. et al. Pharmacokinetics of ramipril in the elderly. Am J Cardiol 1987;59:33D-7D.
20. Todd PA, Heel RC. Enalapril. A review of its pharmacodynamics and pharmacokinetics properties and its therapeutic use in hypertension. Drugs 1986;31:198-248.
21. Obrist WD, Thompson HK, Wang HS, Wilkinson WE. Regional cerebral blood flow estimated by 133-Xenon inhalation. Stroke 1975;6:245-56.
22. Risberg J, Ali Z, Wilson EM, Wills EL, Halsey JH. Regional blood flow by 133-Xenon inhalation. Stroke 1975;6:142-8.
23. de Leeuw PW, Lugtenburg PL, van Houten H, Looman JHM, Birkenhager WH. Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients. J Cardiovasc Pharmacol 1985;7:1161-5.
24. 133Xenon inhalation: accuracy in detection of ischemic cerebral regions and angiographic lesions. In: Wood JH, ed. Cerebral blood flow: physiologic and clinical aspects. New York: McGraw-Hill, 1987:202-19.